Miro Gasparek is the CEO and Co-Founder of Sensible Biotechnologies. Sensible develops a cell-based platform for scalable and cost-effective manufacturing of high-quality mRNA to enable the next generation of mRNA therapies. Sensible Biotechnologies raised a $4.2mn pre-seed round led by BlueYard Capital and closed a strategic partnership with Ginkgo Bioworks for the development of its cell-based mRNA platform.

Miro studied Bioengineering at Imperial College London and did research in systems and synthetic biology at Imperial College, Caltech, and Stanford during his undergraduate studies. Miro worked with TechBio VC investors in the US and Europe and consulted to public institutions and private enterprises in Central and Eastern Europe on life science R&D and business development. He was a graduate research affiliate at Stanford University, where he worked on synthetic biology-associated biosecurity matters. He advised to the Slovak Ministry of Health and Executive Board Member of the World Health Organisation on biosecurity and innovation. Miro is a Co-Managing Director of Nucleate United Kingdom, the world’s largest non-profit organisation supporting student-led life science enterprises. He is also in the final stages of his PhD in Engineering and Synthetic Biology at the University of Oxford.